V-Clamp

Product Introduction

Transapical approach

Transapical implantation.The catheter manipulation timeis about 20 minutes.
Shorter operative time, loweroperative risk.

Minimal invasive surgery

Cardiopulmonary bypass is not required.
Less trauma and complication
Rapid post-operative recovery

Precisely capture leaflet

Smaller-sized delivery system (14F).
Different size of devices can be provided for different mitral annular size and MR pattern.Multiple clips can be implanted for reducing residual MR.

Echo-guided Image

Procedural guiding of the V-clamp implantation with 2D and 3D transesophageal echocardiography (TEE). X-ray fluoroscopy is not necessary.



Hongyu Medical Technology Co., Ltd focuses on treatment of mitral regurgitation for pet canines

Shanghai Hongyu Medical Technology Co., LTD., is a high-tech enterprise dedicated to pet cardiology research, innovative medical device R&D and commercialization. Its core product is the self-developed Mitral Valve Interventional Repair device V CLAMP. It is the only surgical instrument in the world that can be used to treat mitral regurgitation in pet dogs. The company adheres to the concept of innovation and development, with the mission of benefiting the lives of pets.

Tel： 400 100 5433
Add： Building 1，3699 Yuanjiang Road,Minhang District，Shanghai，China
Email: customer_service@hongyumedtech.com

MEDICAL HONGYU

MITRAL VALVE INTERVENTIONAL MEDICAL DEVICES

Focus on the treatment of pet cardiac disease

Company Profile

Shanghai Hongyu Medical Technology Co., LTD., is a high-tech enterprise dedicating to pet cardiology research, innovative medical device R&D and commercialization. Its core product is the self-developed mitral valve Interventional repair device V-CLAMP. It is the only surgical instrument around the world which can be used to treat mitral regurgitation for pet dogs. The company adheres to the concept of innovation and development, with the mission of benefiting the lives of pets.

V-CLAMP is currently in Hospitals and institutions in major cities at home and abroad have successively launched...

frontiers in Veterinary Science

BRIEF RESEARCH REPORT

Preliminary Outcome of a Novel Edge-to-Edge Closure Device to Manage Mitral Regurgitation in Dogs

Bo Liu[1], Stacey B. Leach[2], Wenzhi Pan[3], Fangyu Zheng[1], Liujun Jia[4], Xueying Zhou[1] and Jing Li[1]*

[1] College of Veterinary Medicine, China Agricultural University, Beijing, China, [2] Department of Veterinary Medicine and Surgery, College of Veterinary Medicine, University of Missouri, Columbia, MO, United States, [3] Department of Cardiology, Shanghai Institute of Cardiovascular Diseases, Zhongshan Hospital, Fudan University, Shanghai, China, [4] Beijing Key Laboratory of Pre-Clinic Research and Evaluation for Cardiovascular Implant Materials, Fuwai Hospital National Cardiovascular Centre, Peking Union Medical College and Chinese Academy of Medical Sciences, Beijing, China

Background: Veterinary management of mitral valve regurgitation due to myxomatous valve disease in dogs is limited to medical treatments, which only postpones the onset of congestive heart failure or alleviates clinical symptoms. Most surgical procedures to manage this condition in humans require cardiopulmonary bypass and have a high risk of complications.

Animals: Eight dogs with naturally occurring mitral valve regurgitation.

Methods: Prospective observational study. All dogs were treated with a novel edge-to-edge transcatheter device named ValveClamp. The total surgical procedural time and total catheterization time were recorded. Echocardiographic variables measured pre- and post-procedure were compared using Wilcoxin-signed rank test with a $P < 0.05$ considered significant. Data were expressed as median and interquartile range and absolute numbers and percentages.

Results: The procedural success rate was 100% and all the dogs survived without complications. The median (interquartile range) total surgical procedural time was 86.5 (76-96.2) minutes and catheterization time was 23.5 (22-33.8) minutes. Echocardiography revealed a significant reduction in mitral regurgitation severity in all dogs following the procedure based on both a reduced mitral regurgitant maximum jet area ($P = 0.012$) and a reduced mitral regurgitant maximum jet area to left atrial area ($P = 0.018$).

Conclusion: The ValveClamp device is effective at reducing the severity of mitral regurgitation in dogs with naturally occurring myxomatous valve disease.

Keywords: canine, mitral valve, myxomatous degeneration, transapical, valve surgery

OPEN ACCESS

INTRODUCTION

Related reports

More cases

Country: China
Age：11
Weight：7.3KG
MMVD:B2

Country: China
Age：10
Weight：9.1KG
MMVD:C

Country: China
Age：12
Weight：10KG
MMVD:C



Country: China
Age：9
Weight：4KG
MMVD:C

Country: China
Age：12
Weight：3.2KG
MMVD:C

Country: China
Age：9
Weight：5KG
MMVD:D

Case report

" Datou ", an 8-year-old castrated male schnauzer weighting 8 kg was referred from Guangzhou to Shanghai XinYu Veterinary Cardiovascular Medical Center for further evaluation and treatment on January 8th, 2020. Datou was diagnosed with myxomatous mitral valve disease (stage D) and presented with severe mitral regurgitation and pulmonary hypertension, showed the clinical signs including panting, coughing, exercise intolerance, ascite, mild pulmonary edema and pericardial effusion. After discussion with the owner, the V-Clamp was chosen to perform the transcatheter mitral valve repair.

After the V-clamp repair surgery, there is a significantly reduction in mitral regurgitant volume and " Datou "showed a prominent improvement of cardiac function.







Pre-operative MR



Post-operative MR